Effects of the mixed formulation of sorafenib and blue honeysuckle on the pharmacokinetics profiles of sorafenib
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objective : This study investigated the effects of concentrated and lyophilized blue honeysuckle powders (BH) on the pharmacokinetics (PK) of sorafenib were observed. Method : The blood was collected at 0.5 hr before single oral treatment of sorafenib (40 mg/kg) or sorafenib with BH (400, 200 and 100 mg/kg) mixed formulas administration, and 0.5, 1, 2, 3, 4, 6, 8 and 24 hrs after the end of single or mixed formula administration. Plasma concentrations of sorafenib were analyzed using LC-MS/MS methods. Tmax, Cmax, AUC, t1/2 and MRTinf of sorafenib were analysis as compared with sorafenib single treatment. Results : Single oral administration of mixed formulas induced significant increases of plasma sorafenib concentrations from 0.5 hr after end of administration throughout all blood collected time points, as compared with sorafenib single formula treated rats, and significant decreases of sorafenib Tmax with increases of Cmax, AUC0-t and AUC0-inf were detected in sorafenib and BH 400 mg/kg mixed formulation treated rats as compared with sorafenib single formula treated rats, respectively. Inaddition, sorafenib and BH 200 or 100 mg/kg mixed formula treated rats also showed significant increases of sorafenib Cmax, AUC0-t and AUC0-inf, respectively. Conclusions : According to these results, mixed formulation of BH with sorafenib increased the bioavailability of sorafenib through the increment of the absorptions.
Abstract
Objective : This study investigated the effects of concentrated and lyophilized blue honeysuckle powders (BH) on the pharmacokinetics (PK) of sorafenib were observed. Method : The blood was collected at 0.5 hr before single oral treatment of sorafenib (40 mg/kg) or sorafenib with BH (400, 200 and 100 mg/kg) mixed formulas administration, and 0.5, 1, 2, 3, 4, 6, 8 and 24 hrs after the end of single or mixed formula administration. Plasma concentrations of sorafenib were analyzed using LC-MS/MS methods. Tmax, Cmax, AUC, t1/2 and MRTinf of sorafenib were analysis as compared with sorafenib single treatment. Results : Single oral administration of mixed formulas induced significant increases of plasma sorafenib concentrations from 0.5 hr after end of administration throughout all blood collected time points, as compared with sorafenib single formula treated rats, and significant decreases of sorafenib Tmax with increases of Cmax, AUC0-t and AUC0-inf were detected in sorafenib and BH 400 mg/kg mixed formulation treated rats as compared with sorafenib single formula treated rats, respectively. Inaddition, sorafenib and BH 200 or 100 mg/kg mixed formula treated rats also showed significant increases of sorafenib Cmax, AUC0-t and AUC0-inf, respectively. Conclusions : According to these results, mixed formulation of BH with sorafenib increased the bioavailability of sorafenib through the increment of the absorptions.
참고문헌 (52)
- Bayer, "Nexavar (sorafenib tosylate) tablets prescribing information", ~ (2007)
- Keating GM, "Sorafenib: a review of its use in advanced hepatocellular carcinoma", Drugs, 69(2), pp.223~240 (2009)
- Wilhelm SM, "Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling", Mol Cancer Ther, 7(10), pp.3129~3140 (2008)
- Smalley KS, "CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations", Oncogene, 28(1), pp.85~94 (2009)
- Fabian P, "Molecular predictive markers of EGFR-targeted therapy in metastatic colorectal cancer", Cesk Patol, 47(4), pp.154~158 (2011)
- Kang GH, "Four molecular subtypes of colorectal cancer and their precursor lesions", Arch Pathol Lab Med, 135(6), pp.698~703 (2011)
- Ranieri G, "Sorafenib (BAY 43-9006) in hepatocellular carcinoma patients: from discovery to clinical development", Curr Med Chem, 19(7), pp.938~944 (2012)
- Dasanu CA, "Yellow skin discoloration associated with sorafenib use for treatment of metastatic renal cell carcinoma", South Med J, 100(3), pp.328~330 (2007)
- Alexandrescu DT, "Secondary erythrocytosis produced by the tyrosine kinase inhibitors sunitinib and sorafenib", J Clin Oncol, 26(24), pp.4047~4048 (2008)
- Franck N, "Spiny follicular hyperkeratosis eruption: a new cutaneous adverse effect of sorafenib", J Clin Oncol, 28(31), pp.e640~e642 (2010)
- Liang CP, "Sorafenib-induced acute localized exanthematous pustulosis in a patient with hepatocellular carcinoma", Br J Dermatol, 165(2), pp.443~445 (2011)
- McLellan B, "Cutaneous toxicities of the multikinase inhibitors sorafenib and sunitinib", Dermatol Ther, 24(4), pp.396~400 (2011)
- Siu LL, "Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer", Clin Cancer Res, 12(1), pp.144~151 (2006)
- Ricciardi S, "Synergistic cytotoxicity and molecular interaction on drug targets of sorafenib and gemcitabine in human pancreas cancer cells", Chemotherapy, 56(4), pp.303~312 (2010)
- Kupsch P, "Results of a phase I trial of sorafenib (BAY 43-9006) in combination with oxaliplatin in patients with refractory solid tumors, including colorectal cancer", Clin Colorectal Cancer, 5(3), pp.188~196 (2005)
- Mross K, "Drug-drug interaction pharmacokinetic study with the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with irinotecan (CPT-11) in patients with solid tumors", Int J Clin Pharmacol Ther, 41(12), pp.618~619 (2003)
- Hu S, "Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters", Clin Cancer Res, 15(19), pp.6062~6069 (2009)
- Di Gion P, "Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles", Clin Pharmacokinet, 50(9), pp.551~603 (2011)
- Flaherty KT, "Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I", II pharmacokinetic interaction study, 2011, pp.68(5), 1111~1118
- Infante JR, "A drug interaction study evaluating the pharmacokinetics and toxicity of sorafenib in combination with capecitabine", Cancer Chemother Pharmacol, 69(1), pp.137~144 (2012)
- Moretti LV, "Elevated International Normalized Ratio associated with concurrent use of sorafenib and warfarin", Am J Health Syst Pharm, 66(23), pp.2123~2125 (2009)
- 김승모, "Effect of Gongjindan, a Polyherbal Formula on the Pharmacokinetics Profiles of Sorafenib in Male SD Rats (1) - Single Oral Combination Treatment of Sorafenib 50mg", kg with Gongjindan 100mg, 대한예방한의학회지, pp.2014, 18(2)[DOI]
- 이창형, "Effect of Gongjindan-gamibang on the Pharmacokinetics Profiles of Sorafenib in Male SD Rats (2) - Single Oral Combination Treatment of Sorafenib 50mg", kg with Gongjindan-gamibang 100 mg, 대한예방한의학회지, pp.2015, 19(1)[DOI]
- Svarcova I, "Berry fruits as a source of biologically active compounds: the case of Lonicera caerulea", Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub, 151(2), pp.163~174 (2007)
- Chaovanalikit A, "Characterization and quantification of anthocyanins and polyphenolics in blueh Honeysuckle (Lonicera caerulea L.)", J Agric Food Chem, 52(4), pp.848~852 (2004)
- Zhao H, "Protective effect of anthocyanin from Lonicera Caerulea var. Edulis on radiationinduced damage in mice", Int J Mol Sci, 13(9), pp.11773~11782 (2012)
- Jurgoński A, "An anthocyanin-rich extract from Kamchatka honeysuckle increases enzymatic activity within the gut and ameliorates abnormal lipid and glucose metabolism in rats", Nutrition, 29(6), pp.898~902 (2013)
- Palíková I, "Protectivity of blue honeysuckle extract against oxidative human endothelial cells and rat hepatocyte damage", J Agric Food Chem, 57(15), pp.6584~6589 (2009)
- Jin XH, "Effects of blue honeysuckle (Lonicera caerulea L.) extract on lipopolysaccharide-induced inflammation in vitro and in vivo", Exp Eye Res, 82(5), pp.860~867 (2006)
- Zdarilová A, "Polyphenolic fraction of Lonicera caerulea L. fruits reduces oxidative stress and inflammatory markers induced by lipopolysaccharide in gingival fibroblasts", Food Chem Toxicol, 48(6), pp.1555~1561 (2010)
- Chen L, "Phytochemical properties and antioxidant capacities of various colored berries", J Sci Food Agric, 94(2), pp.180~188 (2014)
- Svobodová A, "Protective effects of phenolic fraction of blue honeysuckle fruits against UVA-induced damage to human keratinocytes", Arch Dermatol Res, 300(5), pp.225~233 (2008)
- Vostálová J, "Lonicera caerulea fruits reduce UVAinduced damage in hairless mice", J Photochem Photobiol B, 128, pp.1~11 (2013)
- 김형수, "Single Oral Dose Toxicity Test of Blue Honeysuckle Concentrate in Mice", 한국독성학회지, 31(1), pp.61~68 (2015), 한국독성학회[DOI]
- AOAC, "Official Methods of Analysis International" (2000), AOAC
- Singleton VL, "The phenolic cinnamates of white grapes and wine", J Sci Food Agric, 29(4), pp.403~410 (1978)
- Yang J, "Varietal differences in phenolic content and antioxidant and antiproliferative activities of onions", J Agric Food Chem, 52(22), pp.6787~6793 (2004)
- Boyles MJ, "Anthocyanin Composition of Red Raspberry Juice: Influences of Cultivar, Processing, and Environmental Factors", J Food Sci, 58(5), pp.1135~1141 (1993)
- Gibaldi M, "Pharmacokinetics" (1982), Marcel-Dekker
- Bailer AJ, "Testing for the equality of area under the curves when using destructive measurement techniques", J Pharmacokinet Biopharm, 16(3), pp.303~309 (1988)
- Chiou WL, "Critical evaluation of the potential error in pharmacokinetic studies of using the linear trapezoidal rule method for the calculation of the area under the plasma level-time curve", J Pharmacokinet Biopharm, 6(6), pp.539~546 (1978)
- Wang XQ, "Bioavailability and pharmacokinetics of sorafenib suspension, nanoparticles and nanomatrix for oral administration to rat", Int J Pharm, 419(1-2), pp.339~346 (2011)
- Tod M, "Functional and clinical evidence of the influence of sorafenib binding to albumin on sorafenib disposition in adult cancer patients", Pharm Res, 28(12), pp.3199~3207 (2011)
- Villarroel MC, "Plasma protein binding of sorafenib, a multi kinase inhibitor: in vitro and in cancer patients", Invest New Drugs, 30(6), pp.2096~2102 (2012)
- Iyer R, "Sorafenib: a clinical and pharmacologic review", Expert Opin Pharmacother, 11(11), pp.1943~1955 (2010)
- Kennoki T, "Clinical results and pharmacokinetics of sorafenib in chronic hemodialysis patients with metastatic renal cell carcinoma in a single center", Jpn J Clin Oncol, 41(5), pp.647~655 (2011)
- Clark JW, "Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors", Clin Cancer Res, 11(15), pp.5472~5480 (2005)
- Hornecker M, "Saturable absorption of sorafenib in patients with solid tumors: a population model", Invest New Drugs, 30(5), pp.1991~2000 (2012)
- Akaza H, "Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma", Jpn J Clin Oncol, 37(10), pp.755~762 (2007)
- Furuse J, "Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma", Cancer Sci, 99(1), pp.159~165 (2008)
- Minami H, "Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors", Cancer Sci, 99(7), pp.1492~1498 (2008)
- Sparidans RW, "Liquid chromatography-tandem mass spectrometric assay for sorafenib and sorafenib-glucuronide in mouse plasma and liver homogenate and identification of the glucuronide metabolite", J Chromatogr B Analyt Technol Biomed Life Sci, 877(3), pp.269~276 (2009)